PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26165106-8 2015 Agents blocking interleukin 1 (canakinumab) can be used in acute gout when NSAIDS and colchicine are contraindicated or not tolerated. Colchicine 86-96 interleukin 1 alpha Homo sapiens 16-29 27110096-8 2016 Anti-IL-1 therapy seems to be a safe and effective alternative for patients with FMF who do not respond to or cannot tolerate colchicine. Colchicine 126-136 interleukin 1 alpha Homo sapiens 5-9 25213327-10 2016 Anti-IL-1 therapies can be successfully used in colchicine-resistant FMF patients and patients with amyloidosis during childhood and adolescent period without major side effects. Colchicine 48-58 interleukin 1 alpha Homo sapiens 5-9 26001859-14 2015 In three patients, anti-IL1 treatment could be stopped and they are fine with colchicine. Colchicine 78-88 interleukin 1 alpha Homo sapiens 24-27 25528863-10 2015 Therefore, controlled trials are needed to evaluate the safety and long-term efficacy of IL-1 targeting agents in colchicine resistant patients. Colchicine 114-124 interleukin 1 alpha Homo sapiens 89-93 25139580-1 2015 Herein, we reported our experience in colchicine-resistant familial Mediterranean fever (FMF) patients who are treated with anti-interleukin-1 (IL-1) drugs. Colchicine 38-48 interleukin 1 alpha Homo sapiens 124-142 25139580-1 2015 Herein, we reported our experience in colchicine-resistant familial Mediterranean fever (FMF) patients who are treated with anti-interleukin-1 (IL-1) drugs. Colchicine 38-48 interleukin 1 alpha Homo sapiens 144-148 25139580-10 2015 Anti-IL-1 targeting drugs seem safe and effective therapies in colchicine-resistant FMF. Colchicine 63-73 interleukin 1 alpha Homo sapiens 5-9 24667287-7 2014 When colchicine fails, IL-1 blockade is effective. Colchicine 5-15 interleukin 1 alpha Homo sapiens 23-27 24667287-13 2014 IL-1 blockade appears effective, but larger prospective trials are needed, especially in MKD, TRAPS and colchicine-resistant FMF patients. Colchicine 104-114 interleukin 1 alpha Homo sapiens 0-4 21277619-10 2011 The reasons for using interleukin-1 targeting drugs in FMF patients were as follows: (1) incomplete control of disease activity despite colchicine treatment; (2) high serum amyloid A levels despite colchicine treatment; (3) impossibility to use colchicine treatment because of severe side effects; (4) FMF in association with vasculitis. Colchicine 136-146 interleukin 1 alpha Homo sapiens 22-35 23742958-7 2013 In case of persistent attacks (>=6 per year) in patients with maximum doses of colchicine (2 mg in children; 3 mg in adults), alternative treatment to colchicine with IL1 inhibitors should be considered. Colchicine 154-164 interleukin 1 alpha Homo sapiens 170-173 23697917-5 2013 Consequently, IL-1 blocking strategies are specific pathway targeting therapies in autoinflammatory diseases and applied in CAPS, colchicine-resistant FMF, TRAPS, HIDS and DIRA. Colchicine 130-140 interleukin 1 alpha Homo sapiens 14-18 22884553-7 2012 Anti-IL-1 treatment is also effective in FMF patients resistant or partially responsive to colchicine. Colchicine 91-101 interleukin 1 alpha Homo sapiens 5-9 21277619-10 2011 The reasons for using interleukin-1 targeting drugs in FMF patients were as follows: (1) incomplete control of disease activity despite colchicine treatment; (2) high serum amyloid A levels despite colchicine treatment; (3) impossibility to use colchicine treatment because of severe side effects; (4) FMF in association with vasculitis. Colchicine 198-208 interleukin 1 alpha Homo sapiens 22-35 21277619-10 2011 The reasons for using interleukin-1 targeting drugs in FMF patients were as follows: (1) incomplete control of disease activity despite colchicine treatment; (2) high serum amyloid A levels despite colchicine treatment; (3) impossibility to use colchicine treatment because of severe side effects; (4) FMF in association with vasculitis. Colchicine 198-208 interleukin 1 alpha Homo sapiens 22-35 21277619-11 2011 CONCLUSIONS: Interleukin-1 targeting drugs may be good candidates when looking for an alternative or supplementary treatment to colchicine. Colchicine 128-138 interleukin 1 alpha Homo sapiens 13-26 21159830-3 2011 We report the effect of anti-tumor necrosis factor therapy (etanercept) and anti-interleukin 1 (IL-1) treatment (anakinra) in 6 cases resistant to colchicine therapy. Colchicine 147-157 interleukin 1 alpha Homo sapiens 76-100 9452460-2 1998 We have demonstrated previously that microtubule depolymerization by colchicine in human monocytes induces selective production of interleukin-1 (IL-1) (Manie, S., Schmid-Alliana, A., Kubar, J., Ferrua, B., and Rossi, B. Colchicine 69-79 interleukin 1 alpha Homo sapiens 131-144 11154858-4 2001 Colchicine also inhibited VCAM-1 induction on both TNFalpha- and IL-1alpha-stimulated human umbilical vein endothelial cells (HUVEC). Colchicine 0-10 interleukin 1 alpha Homo sapiens 65-74 9452460-2 1998 We have demonstrated previously that microtubule depolymerization by colchicine in human monocytes induces selective production of interleukin-1 (IL-1) (Manie, S., Schmid-Alliana, A., Kubar, J., Ferrua, B., and Rossi, B. Colchicine 69-79 interleukin 1 alpha Homo sapiens 146-150 9452460-11 1998 The importance of Src kinases in the mediation of the colchicine effect is underscored by the fact that CP 118556, a specific inhibitor of Src-like kinase, abrogates both the colchicine-induced ERK activation and IL-1 production. Colchicine 54-64 interleukin 1 alpha Homo sapiens 213-217 33813772-0 2021 The efficacy of interleukin-1 antagonist drugs in combination with colchicine in patients with FMF-AA with colchicine-resistance after kidney transplantation: A study with histopathologic evidence. Colchicine 107-117 interleukin 1 alpha Homo sapiens 16-29 8099911-5 1993 These results suggested that the colchicine-mediated IL-1 induction was generated by microtubule disassembly. Colchicine 33-43 interleukin 1 alpha Homo sapiens 53-57 8099911-7 1993 The use of different protein kinase inhibitors supported a role of the PKA, but not the PKC, in the colchicine-induced IL-1 production. Colchicine 100-110 interleukin 1 alpha Homo sapiens 119-123 8099911-8 1993 Furthermore, elevation of intracellular cAMP levels by 8-bromo-cAMP, forskolin, or cholera toxin potentiated the effect of suboptimal concentration of colchicine on IL-1 synthesis. Colchicine 151-161 interleukin 1 alpha Homo sapiens 165-169 8099911-2 1993 We have reported recently that colchicine and other microtubule-disrupting agents stimulated interleukin-1 (IL-1) alpha and beta synthesis in human monocytes. Colchicine 31-41 interleukin 1 alpha Homo sapiens 93-106 8099911-2 1993 We have reported recently that colchicine and other microtubule-disrupting agents stimulated interleukin-1 (IL-1) alpha and beta synthesis in human monocytes. Colchicine 31-41 interleukin 1 alpha Homo sapiens 108-119 1793049-4 1991 Colchicine partly inhibited the secretion of IL-1 by neutrophils during phagocytosis of solid particles. Colchicine 0-10 interleukin 1 alpha Homo sapiens 45-49 1793049-5 1991 However, colchicine selectively inhibited IL-1 synthesis induced by microcrystals. Colchicine 9-19 interleukin 1 alpha Homo sapiens 42-46 2242502-3 1990 On the contrary, microtubule disrupters such as colchicine, vinblastine, and vincristine dramatically potentiate (15- to 35-fold), in a dose-dependent fashion, cell-associated IL1 and to a lesser extent (2.5- to 7-fold) released IL1 in the myelomonocytic THP1 cell line and in adherent peripheral blood mononuclear cells. Colchicine 48-58 interleukin 1 alpha Homo sapiens 176-179 2242502-3 1990 On the contrary, microtubule disrupters such as colchicine, vinblastine, and vincristine dramatically potentiate (15- to 35-fold), in a dose-dependent fashion, cell-associated IL1 and to a lesser extent (2.5- to 7-fold) released IL1 in the myelomonocytic THP1 cell line and in adherent peripheral blood mononuclear cells. Colchicine 48-58 interleukin 1 alpha Homo sapiens 229-232 1981242-10 1990 Colchicine inhibited IL-1 activity but not IL-1 production. Colchicine 0-10 interleukin 1 alpha Homo sapiens 21-25 33813772-1 2021 BACKGROUND: The efficacy of anti-interleukin-1 (IL-1) drugs in kidney transplant patients with FMF-AA who developed colchicine-resistance has not been clearly demonstrated. Colchicine 116-126 interleukin 1 alpha Homo sapiens 33-46 35127599-20 2021 Secondary amyloidosis is still happening in adults however, it is extremely rare among children, presumably due to increased awareness, tight control, and the availability of anti-IL1 agents in colchicine-resistant cases. Colchicine 194-204 interleukin 1 alpha Homo sapiens 180-183 35113170-3 2022 Since colchicine is an anti-inflammatory drug with the ability to block NLRP3 inflammasome oligomerization, this may prevent the release of active IL-1beta and block the detrimental effects of downstream cytokines, i.e. IL-6. Colchicine 6-16 interleukin 1 alpha Homo sapiens 147-155 34858402-1 2021 Background: Interleukin (IL)-1 inhibitors represent the main treatment in patients with colchicine-resistant/intolerant familial Mediterranean fever (crFMF), mevalonate kinase deficiency (MKD), and tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Colchicine 88-98 interleukin 1 alpha Homo sapiens 12-30 34686461-12 2022 Colchicine patients had numerically lower levels of pre-PCI cytokines: IL-1beta (p = 0.01), IL-6 (p = 0.02), IL-10 (p = 0.01), IFNgamma (p = 0.01), TNFalpha (p = 0.02) and WBC-count (p = 0.04). Colchicine 0-10 interleukin 1 alpha Homo sapiens 71-79 34568239-1 2021 Anti-interleukin 1 agents are used successfully in colchicine-resistant or intolerant Familial Mediterranean Fever (FMF) patients. Colchicine 51-61 interleukin 1 alpha Homo sapiens 5-18 35178861-15 2022 In both CVB3 FB and HL-1 cells, colchicine down-regulated the NLRP3 inflammasome-related components ASC, caspase-1, and IL-1beta. Colchicine 32-42 interleukin 1 alpha Homo sapiens 120-128 33295622-16 2021 CONCLUSION: In patients who were refractory to colchicine, anti-IL-1 agent anakinra was shown to be effective and safe. Colchicine 47-57 interleukin 1 alpha Homo sapiens 64-68 6809339-0 1982 Modulation of interleukin 1 production by activated macrophages: in vitro action of hydrocortisone, colchicine, and cytochalasin B. Colchicine 100-110 interleukin 1 alpha Homo sapiens 14-27 33593369-5 2021 Colchicine has many anti-inflammatory and cardiovascular protective properties, including inhibition of IL-1beta and IL-18 activity, key proinflammatory cytokines that are predictive of future adverse cardiovascular events. Colchicine 0-10 interleukin 1 alpha Homo sapiens 104-112 33930279-5 2021 IL-1beta, IL-6 and osteopontin (OPN) were more strongly inhibited by SAC than in colchicine. Colchicine 81-91 interleukin 1 alpha Homo sapiens 0-8 33913256-6 2021 Independent of MEFV genotype, unstimulated FMF monocytes from colchicine treated patients secreted lower amounts of IL1Ralpha as compared to healthy donors (p<0.05) and displayed decreased ratios of IL1Ralpha/IL1beta (p<0.05), suggesting a reduced anti-inflammatory capacity. Colchicine 62-72 interleukin 1 alpha Homo sapiens 209-216 32306038-0 2020 Anti-IL1 treatment in colchicine-resistant paediatric FMF patients: real life data from the HELIOS registry. Colchicine 22-32 interleukin 1 alpha Homo sapiens 5-8 33551814-3 2020 We conducted a nested case-control study by using the US Food and Drug Administration Adverse Event Reporting System database aimed at quantifying the association between the use of IL-1 inhibitors/colchicine in pregnant women and the occurrence of maternal/fetal adverse effects. Colchicine 198-208 interleukin 1 alpha Homo sapiens 182-186 32966192-5 2021 RESULTS: Remission was achieved in arthritis attacks in 16 of 18 patients who started anti-IL-1 therapy because of colchicine-resistant chronic arthritis. Colchicine 115-125 interleukin 1 alpha Homo sapiens 91-95 32966192-7 2021 The treatment dose of colchicine was reduced with anti-IL-1 therapy. Colchicine 22-32 interleukin 1 alpha Homo sapiens 55-59 32966192-10 2021 CONCLUSION: Anti-IL-1 therapy is effective and reliable in the treatment of colchicine-resistant chronic FMF arthritis. Colchicine 76-86 interleukin 1 alpha Homo sapiens 17-21 32966192-11 2021 The efficacy of anti-IL-1 therapy was realized without concomitant disease-modifying antirheumatic drug therapy, despite the reduction in colchicine dose. Colchicine 138-148 interleukin 1 alpha Homo sapiens 21-25 32806879-8 2020 Experience of IL-1 antagonists, anakinra and canakinumab, is now available in thousands of colchicine resistant or intolerant FMF patients. Colchicine 91-101 interleukin 1 alpha Homo sapiens 14-18 32306038-2 2020 Anti-IL1 treatments are the first-line alternatives in colchicine-resistant/intolerant FMF patients. Colchicine 55-65 interleukin 1 alpha Homo sapiens 5-8 32598947-7 2020 The ability of the colchicine analogues with the predicted highest affinity for betaVI-tubulin to dampen neutrophil responses to MSU was determined with in vitro assays that measure MSU-induced production of ROS, release of IL-1 and IL-8, and the increase in the concentration of cytoplasmic calcium. Colchicine 19-29 interleukin 1 alpha Homo sapiens 224-228 32645635-5 2020 Our observations suggest that blocking IL-1 is a safe and an effective alternative for colchicine resistant FMF and probably also for associated MS. Colchicine 87-97 interleukin 1 alpha Homo sapiens 39-43 32533192-10 2020 CONCLUSION: Anti-IL-1 therapies (i.e. anakinra and canakinumab) appear to be effective and safe options in the treatment of overall FMF, including patients with colchicine resistance and FMF-related amyloidosis. Colchicine 161-171 interleukin 1 alpha Homo sapiens 17-21 32398478-1 2020 Interleukin-1 (IL-1) receptor antagonist (anakinra) has been shown to be effective in steroid-dependent recurrent pericarditis resistant to nonsteroidal anti-inflammatory drugs (NSAIDs) and colchicine. Colchicine 190-200 interleukin 1 alpha Homo sapiens 0-13 32477360-13 2020 In conclusion, we suggest that in the presence of intolerance or resistance to colchicine, interleukin (IL)-1 inhibition could suppress peritoneal inflammation and prevent MSTs. Colchicine 79-89 interleukin 1 alpha Homo sapiens 91-109 29981275-2 2018 Anti-interleukin-1 drugs emerge as a therapeutic option for colchicine-resistant patients. Colchicine 60-70 interleukin 1 alpha Homo sapiens 5-18 28302131-11 2017 Interleukin 1-targeting drugs represented the only alternative treatments in addition to daily colchicine. Colchicine 95-105 interleukin 1 alpha Homo sapiens 0-13 27328763-8 2017 Sixteen patients with colchicine resistance had no attacks under anti-IL-1 treatment, and 4 had decreased frequency and duration of attacks. Colchicine 22-32 interleukin 1 alpha Homo sapiens 70-74 27328763-13 2017 CONCLUSION: Anti-IL-1 agents are rational treatment modalities in patients resistant or intolerant to colchicine. Colchicine 102-112 interleukin 1 alpha Homo sapiens 17-21 32808940-4 2020 Studies show that colchicine, among other actions, inhibits the assembly of NLRP3 complex that is responsible for generating the active form of Caspase-1 that will convert Pro-IL-1beta and Pro-IL-18 into their active forms. Colchicine 18-28 interleukin 1 alpha Homo sapiens 176-184 32558310-2 2020 We also evaluate the quality of life and school attendance among colchicine-resistant FMF patients, in relation to treatment with anti-IL-1. Colchicine 65-75 interleukin 1 alpha Homo sapiens 135-139 32558310-5 2020 Anti-IL-1 treatment is promising in colchicine-resistant patients due to excessive IL-1beta production in pathogenesis. Colchicine 36-46 interleukin 1 alpha Homo sapiens 5-9 32558310-5 2020 Anti-IL-1 treatment is promising in colchicine-resistant patients due to excessive IL-1beta production in pathogenesis. Colchicine 36-46 interleukin 1 alpha Homo sapiens 83-91 32558310-6 2020 The aim of this study is to evaluate the quality of life and school attendance rates among colchicine-resistant FMF patients after anti-IL-1 treatment. Colchicine 91-101 interleukin 1 alpha Homo sapiens 136-140 32558310-7 2020 METHODS: This is a single center retrospective study of 25 pediatric colchicine-resistant FMF patients treated with anti-IL-1 treatment. Colchicine 69-79 interleukin 1 alpha Homo sapiens 121-125 32558310-14 2020 CONCLUSION: Anti-IL-1 treatment is quite effective in children with colchicine-resistant FMF patients, proven with improved AIDAI scores and school attendance rates. Colchicine 68-78 interleukin 1 alpha Homo sapiens 17-21 31383341-3 2019 Interleukin-1 (IL-1) blockers could be used in colchicine resistant cases. Colchicine 47-57 interleukin 1 alpha Homo sapiens 0-13 31383341-3 2019 Interleukin-1 (IL-1) blockers could be used in colchicine resistant cases. Colchicine 47-57 interleukin 1 alpha Homo sapiens 15-19 31383341-4 2019 However, starting IL-1 blocker treatment after colchicine failure may lose opportunity for effective treatment. Colchicine 47-57 interleukin 1 alpha Homo sapiens 18-22 31185840-5 2019 Therefore, antagonists against interleukin 1 or IL-1 receptors can be used for treatment if colchicine, steroids or nonsteroidal anti-inflammatory drugs are ineffective or contraindicated. Colchicine 92-102 interleukin 1 alpha Homo sapiens 31-44 31365342-5 2019 In colchicine-resistant or intolerant patients, recent insights into the pathogenesis of FMF have made the anti-IL1 treatments important. Colchicine 3-13 interleukin 1 alpha Homo sapiens 112-115 29578360-3 2019 Efficacy of interleukin (IL)-1 inhibitors in reducing attacks have been demonstrated in colchicine-resistant FMF (crFMF) patients recently. Colchicine 88-98 interleukin 1 alpha Homo sapiens 12-30 30501849-0 2018 IL1-blocking therapy in colchicine-resistant familial Mediterranean fever. Colchicine 24-34 interleukin 1 alpha Homo sapiens 0-3 28992387-8 2018 Anti-IL-1 treatment was used because of colchicine-resistant disease in 84% and amyloidosis in 12% of subjects. Colchicine 40-50 interleukin 1 alpha Homo sapiens 5-9 28992387-11 2018 CONCLUSION: Anti-IL-1 treatment is an effective alternative for controlling attacks and decreasing proteinuria in colchicine-resistant FMF patients. Colchicine 114-124 interleukin 1 alpha Homo sapiens 17-21 28497352-6 2017 Colchicine is still the mainstay of FMF therapy, but IL-1 blockade is also effective if colchicine fails. Colchicine 88-98 interleukin 1 alpha Homo sapiens 53-57